Davalintide
moderate riskAlso: AC2307 · Amylin analog (2nd gen)
Davalintide is a second-generation amylin analog developed by Amylin Pharmaceuticals (now part of AstraZeneca). More potent and longer-acting than pramlintide. Phase II trials showed weight loss but development was discontinued in favor of combination approaches. Predecessor to the amylin analog class that includes cagrilintide.
Reported Benefits
Weight loss
Phase II: significant weight loss vs. placebo; development discontinued before Phase III.
Mechanism of Action
Amylin receptor agonist — reduces food intake via area postrema and hypothalamic satiety signaling; slows gastric emptying; reduces glucagon secretion.
Development History
Davalintide demonstrated clinical proof-of-concept for second-generation amylin agonism but was discontinued before Phase III. Lessons from its development informed cagrilintide’s design — particularly the value of amylin+GLP-1 combination approaches that became CagriSema.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Nausea
- •Vomiting
- •Injection site reactions
Contraindications
- •Pregnancy
- •Severe GI motility disorders
Drug Interactions
- •Insulin
Primary Uses
Related Peptides
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Davalintide?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →